m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05732
 [1]
m6A modification MIR675 MIR675 METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA microRNA-675 PPP1R12A  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target microRNA 675 (MIR675)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator MicroRNA 675 (MIR675) microRNA View Details
Regulated Target myosin phosphatase targeting protein 1 (MYPT1) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL3-mediated m6A modifications were essential for sustaining the stability of microRNA 675 (MIR675), and silencing of METTL3 restrained tumorigenesis of GISTs cells by regulating the microRNA-675/myosin phosphatase targeting protein 1 (MYPT1) axis.
Responsed Disease Gastrointestinal stromal tumor ICD-11: 2B5B
 Disease Info 
Cell Process Cell apoptosis
In-vitro Model
 GIST-T1 Gastrointestinal stromal tumor Homo sapiens CVCL_4976
GIST882 Gastrointestinal stromal tumor Homo sapiens CVCL_7044
In-vivo Model the GIST-T1 cells were injected into the back flanks of the C57BL/6 female mice (Age six-week-old) at the concentration of 1 × 106 cells diluting in 200 μl PBS buffer solution. The GIST-T1 cells were allowed to grow in mice for a total of 25 days, the mice were sacrificed at day 25 and the tumors were obtained and weighed to evaluate the tumorigenesis abilities of the GIST-T1 cells in vivo.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2B5B: Gastrointestinal stromal tumor 11 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Avapritinib Approved [2]
Synonyms
1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine
    Click to Show/Hide
External Link
CID: 118023034
TTD: D0UO2P
DrugBank: DB15233
 Compound Name Sunitinib Approved [3]
Synonyms
Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)
    Click to Show/Hide
External Link
CID: 5329102
TTD: D0R0MW
DrugBank: DB01268
 Compound Name Ripretinib Approved [4]
Synonyms
1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-
    Click to Show/Hide
External Link
CID: 71584930
TTD: D09AAK
DrugBank: DB14840
 Compound Name Bezuclastinib Phase 3 [5]
Synonyms
1616385-51-3; 1H-Pyrazole-3-carboxamide, 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-; 2ROQ545LAG; 3,4-dimethyl-N-(2-phenyl-1H- pyrrolo[2,3-b]pyridin-5-yl)-1H- pyrazole-5-carboxamide; 3,4-Dimethyl-N-(2-phenyl-1H-pyrrolo(2,3-b)pyridin-5-yl)-1H-pyrazole-5-carboxamide; 3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5-carboxamide; 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-3-carboxamide; BDBM392363; Bezuclastinib; BEZUCLASTINIB [INN]; BEZUCLASTINIB [USAN]; Bezuclastinib [WHO-DD]; CGT9486; CGT-9486; CHEMBL5095229; CS-0376032; EX-A5975; GLXC-26827; GTPL11868; HY-145557; MS-24986; NVSHVYGIYPBTEZ-UHFFFAOYSA-N; PLX 9486 [WHO-DD]; PLX9486; PLX-9486; SCHEMBL15824576; UNII-2ROQ545LAG; US10301280, Compound P-2007; US10301280, Compound P-2164; WEJ
    Click to Show/Hide
External Link
CID: 75593308
TTD: DLC7Y9
 Compound Name Masitinib Phase 3 [6]
Synonyms
790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
    Click to Show/Hide
External Link
CID: 10074640
TTD: D0MW0N
DrugBank: DB11526
 Compound Name CP-868596 Phase 3 [6]
Synonyms
Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
    Click to Show/Hide
External Link
CID: 10366136
TTD: D0J1GR
DrugBank: DB11832
 Compound Name BIIB 2024 Phase 2 [7]
External Link
TTD: D0J8BZ
 Compound Name PLX9486 Phase 1/2 [8]
Synonyms
CGT9486
    Click to Show/Hide
External Link
TTD: D03MDY
 Compound Name DS-6157 Phase 1 [9]
External Link
TTD: DJ4X7D
 Compound Name XmAb18087 Phase 1 [6]
External Link
TTD: D0FU0O
 Compound Name CDX-0158 Phase 1 [10]
External Link
TTD: D03HKR
References
Ref 1 N6-methyladenosine-modified microRNA-675 advances the development of gastrointestinal stromal tumors via inhibiting myosin phosphatase targeting protein 1. Genomics. 2023 Sep;115(5):110704. doi: 10.1016/j.ygeno.2023.110704. Epub 2023 Sep 9.
Ref 2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 3 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 5 ClinicalTrials.gov (NCT05208047) A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors. U.S.National Institutes of Health.
Ref 6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 7 ClinicalTrials.gov (NCT00574236) Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 8 ClinicalTrials.gov (NCT02401815) CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 9 ClinicalTrials.gov (NCT04276415) DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST). U.S. National Institutes of Health.
Ref 10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)